Tadalafil (Generic) Pregnancy and Lactation Safety

How Tadalafil Works: PDE5 Inhibition and Vascular Smooth Muscle

Tadalafil inhibits phosphodiesterase type 5 (PDE5), an enzyme that degrades cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. By blocking PDE5, tadalafil allows cGMP to accumulate, which relaxes smooth muscle in the corpus cavernosum and increases penile blood flow during sexual stimulation 1.

PDE5 is not limited to erectile tissue. It is expressed in pulmonary vasculature, the bladder neck, the prostate, and systemic arterioles 2. This broader distribution explains why tadalafil also holds FDA approval for pulmonary arterial hypertension (marketed as Adcirca at 40 mg) and for benign prostatic hyperplasia symptoms at 5 mg daily. The drug's 17.5-hour half-life, substantially longer than sildenafil's 4 hours, supports once-daily dosing and produces steady-state plasma concentrations within 5 days 3.

Understanding this vascular mechanism matters for pregnancy discussions because PDE5 is also present in uterine and placental vasculature. That expression has driven research interest in whether PDE5 inhibitors could modify uteroplacental blood flow, a question explored in preeclampsia trials using related compounds.

FDA Pregnancy Labeling: What the Label Actually States

Tadalafil was classified as Pregnancy Category B under the former FDA letter system. That designation means animal reproduction studies failed to demonstrate fetal risk, but no adequate, well-controlled studies have been conducted in pregnant women 3.

The FDA's prescribing information states directly: "Tadalafil is not indicated for use in women" 3. This language appears in both the Cialis and the generic tadalafil labels. Since 2015, the FDA has replaced letter categories with the Pregnancy and Lactation Labeling Rule (PLLR), which requires narrative summaries of available human data, animal data, and pharmacologic risk 4. Generic tadalafil labels updated after 2015 follow this format, removing the "Category B" shorthand and replacing it with descriptive risk assessments.

The Endocrine Society's 2018 guideline on testosterone therapy notes that clinicians should "evaluate the reproductive implications of any concomitant medications, including PDE5 inhibitors, when counseling men with fertility goals" 5. This recommendation underscores that even drugs with favorable animal profiles warrant a conversation when conception is being planned.

Category B, despite sounding reassuring, does not mean "safe in pregnancy." It means only that we lack human evidence of harm.

Animal Reproductive Toxicology: The Preclinical Record

The preclinical safety profile of tadalafil in reproduction comes from studies in rats and mice conducted during the original Cialis NDA submission. In embryo-fetal development studies, pregnant rats received oral tadalafil at doses producing systemic exposures up to 45 times the maximum recommended human dose (MRHD) based on AUC comparisons. No teratogenicity or structural malformations were observed at any dose tested 3.

At the highest doses (approximately 10x the MRHD by AUC), fetal body weights showed slight reductions in rat pups 3. Postnatal survival and development remained normal. No effects on fertility indices, mating behavior, or litter size emerged in rat fertility studies at exposures exceeding human therapeutic levels by a wide margin.

These results are consistent with the broader PDE5 inhibitor class. Sildenafil and vardenafil also passed animal teratogenicity screens without structural findings. The absence of developmental toxicity at supratherapeutic exposures provides moderate preclinical reassurance, but extrapolation from rodent physiology to human placentation has well-documented limitations. Rat placentas are hemochorial like human placentas, which supports some degree of translatability, yet differences in implantation depth and trophoblast invasion make direct equivalence unreliable 6.

Human Pregnancy Data: Gaps in the Evidence

No randomized controlled trials have evaluated tadalafil use by pregnant women. This evidence gap is large and unlikely to close through traditional trial design, because enrolling pregnant subjects in studies of a drug with no maternal indication presents ethical barriers that review boards will not waive.

The available human data is limited to case reports and small observational series. A few case reports describe women with pulmonary arterial hypertension who continued tadalafil (marketed as Adcirca, 40 mg) through pregnancy under close hemodynamic monitoring. The published outcomes in these reports were favorable, with no reported congenital anomalies, but the sample sizes (single digits) cannot rule out rare adverse effects 7.

No pregnancy registry exists for tadalafil. For comparison, sildenafil has been studied more extensively in pregnancy-related conditions. The STRIDER consortium randomized women with severe early-onset fetal growth restriction to sildenafil 25 mg three times daily versus placebo across multiple countries. The Dutch arm was discontinued after an interim analysis found a higher rate of neonatal pulmonary hypertension in the sildenafil group 8. While tadalafil was not the drug studied in STRIDER, the finding raised class-wide caution about PDE5 inhibitors and fetal pulmonary vasculature.

The FDA label summarizes the situation plainly: "There are no adequate and well-controlled studies of tadalafil in pregnant women" 3.

Male Partner Use: Does Tadalafil Affect Conception or the Fetus?

Most pregnancy-related tadalafil questions come from men taking 5 to 20 mg for erectile dysfunction whose partners are pregnant or trying to conceive. The pharmacokinetic data here is reassuring. Tadalafil is present in semen, but the concentration is approximately 0.5% of plasma levels 3. At a 20 mg dose, peak plasma concentration reaches roughly 378 ng/mL, placing seminal concentrations at approximately 1.9 ng/mL. The resulting vaginal mucosal exposure is far below any pharmacologically active threshold.

Regarding direct effects on sperm, a 2007 study by Pomara and colleagues measured semen parameters in 20 young infertile men after single doses of tadalafil 20 mg. Sperm motility showed a modest increase in progressive motility within 3 hours post-dose compared to baseline 9. No adverse effects on sperm morphology or DNA fragmentation were identified. Total sperm count was unaffected.

A separate in-vitro analysis found that PDE5 inhibitors at therapeutic concentrations did not impair acrosome reaction timing or capacitation in washed human spermatozoa 2. Taken together, these findings suggest that tadalafil at standard doses (2.5 to 20 mg) does not harm sperm function and may slightly favor motility, though the clinical significance of that effect remains uncertain.

Men taking tadalafil do not need to discontinue the drug solely because a partner is pregnant or planning to conceive, based on current evidence. The drug does not accumulate in seminal fluid at levels that could affect an embryo.

PDE5 Inhibitors in Pregnancy-Related Conditions: Ongoing Research

Researchers have explored PDE5 inhibitors for two pregnancy complications where impaired uteroplacental perfusion plays a central role: preeclampsia and fetal growth restriction (FGR). The hypothesis is logical. PDE5 is expressed in myometrial and placental vascular smooth muscle 10. Inhibiting it could theoretically increase uterine artery blood flow and reduce placental ischemia.

Most clinical trials in this space have used sildenafil rather than tadalafil, given sildenafil's shorter half-life and more extensive safety record. The STRIDER trials enrolled women with severe early-onset FGR at <30 weeks gestation 8. Results were mixed across national arms, and the Dutch arm's finding of excess neonatal persistent pulmonary hypertension of the newborn (PPHN) cases prompted early termination.

Whether tadalafil would produce similar fetal pulmonary effects remains unknown. Its longer half-life (17.5 hours versus 4 hours for sildenafil) means sustained PDE5 inhibition, which could theoretically amplify any fetal vascular effect, positive or negative. No completed trial has administered tadalafil to pregnant women for preeclampsia or FGR, and the STRIDER safety signal has dampened enthusiasm for new PDE5 inhibitor trials in this population.

For women with pulmonary arterial hypertension who become pregnant, current ESC/ERS guidelines recommend continued PAH-specific therapy because the maternal mortality risk of untreated PAH in pregnancy is 16 to 30% 7. In such cases, the benefit-risk calculation may favor continuing tadalafil under specialist supervision, but this is a rare, high-acuity clinical scenario managed by maternal-fetal medicine teams.

Tadalafil and Lactation: What the Data Show

Published human lactation data for tadalafil does not exist. The FDA label states that tadalafil is excreted in rat breast milk at concentrations approximately 2.4 times higher than concurrent plasma levels 3. Whether the same ratio applies in humans is unknown.

The drug's molecular weight (389.4 Da), high protein binding (94%), and moderate lipophilicity suggest that some transfer into human milk is plausible. However, oral bioavailability in the nursing infant would be reduced by first-pass hepatic metabolism, and the absolute amount transferred (based on a 20 mg maternal dose) would likely be low. The LactMed database, maintained by the National Library of Medicine, notes the absence of human data and recommends caution without issuing a firm contraindication 11.

For breastfeeding women who require tadalafil for pulmonary arterial hypertension, the decision involves weighing maternal health stability against theoretical neonatal exposure. This is a shared decision between the patient, the prescribing pulmonologist, and the pediatrician. For the more common scenario of a male partner taking tadalafil, lactation exposure through seminal transfer to the mother and then to milk is pharmacologically negligible.

Clinical Recommendations: A Practical Framework

The clinical path depends on who is taking tadalafil and why.

Male partners taking tadalafil 2.5 to 20 mg for ED or BPH: No discontinuation is necessary before conception or during a partner's pregnancy. Seminal drug concentrations are pharmacologically irrelevant. Continue the prescribed regimen and inform the prescriber about family planning goals, particularly if the patient is also taking testosterone (which does impair spermatogenesis) 5.

Women taking tadalafil 40 mg for PAH who become pregnant: Do not stop the drug without consulting the treating pulmonologist. Abrupt withdrawal of PAH therapy carries mortality risk. Current ESC/ERS guidelines support continued therapy with close fetal surveillance, ideally managed at a center with maternal-fetal medicine and PAH expertise 7.

Women who are breastfeeding: If a male partner is taking tadalafil, no adjustment is needed. If a woman herself is taking tadalafil for PAH and wishes to breastfeed, discuss infant monitoring strategies with the pediatrician. The theoretical milk transfer is low, but no human data confirms safety.

Tadalafil's 17.5-hour half-life means that steady-state clearance after discontinuation takes approximately 5 days (five half-lives). For any clinical scenario requiring a drug-free interval before conception or a procedure, plan for at least a 5-day washout.